Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Gilead Sciences

Look Out Below If You Still Own 7 Stocks When The Crash Comes

No one knows when the next S&P 500 crash will hit. But everyone should know which stocks to watch out for.

Investors Business Daily

Gilead Sciences' Q2 2024 Earnings: What to Expect

Gilead Sciences is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit increase.

Barchart

HIV breakthrough: drug trial shows injection twice a year is 100% effective against infection

A large clinical trial in South Africa and Uganda has shown that a twice-yearly injection of a new pre-exposure prophylaxis drug gives young women total protection from HIV infection.

The Conversation

From analysis to the latest developments in health,
read the most diverse news in one place.

Why A Broken Wing Butterfly Might Make Money In Gilead Sciences Stock

Support for Gilead shares sits near 57.

Investors Business Daily

Is Gilead Sciences Stock Underperforming the Nasdaq?

Gilead Sciences has recently underperformed the broader Nasdaq Composite, but analysts are reasonably bullish about the stock’s outlook.

Barchart

Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar

Gilead stock jumped Friday after surprising Wall Street with preclinical test results for an under-the-radar weight-loss drug.

Investors Business Daily

3 Dividend Growth Stocks to Buy and Hold

These three dividend-paying growth stocks are worth a look at current levels as the odds rise for Fed rate cuts.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Gilead Sciences Stock Outlook: Is Wall Street Bullish or Bearish?

Gilead Sciences has underperformed the broader market YTD, but Wall Street analysts are still cautiously optimistic about the stock’s prospects.

Barchart

Is Gilead Sciences Stock a Buy Near 52-Week Lows for Its 4% Yield?

Gilead Sciences stock has trailed the broader markets by a significant margin over the last eight years. Is this high-yield dividend stock a good buy right now?

Barchart

CymaBay Rockets After Gilead Snaps Up The Liver-Focused Biotech For $4.3 Billion

CymaBay stock skyrocketed Monday after Gilead Sciences announced it will buy it for $4.3 billion. CBAY stock surged almost 25%.

Investors Business Daily

How To Invest: The Slow Saucer Base Can Produce Quick Returns

Though it can technically be as short as seven weeks, most saucer bases develop over months or even years.

Investors Business Daily

Is Gilead's 10% Crash — Resulting In A Failed Breakout — An Overreaction?

Gilead said Monday its drug, Trodelvy, failed to pass muster in a study of patients with lung cancer, and GILD stock toppled.

Investors Business Daily

Gilead Sciences (GILD) Earnings Forecast and Gameplan

Gilead Sciences (GILD) boasts an impressive product portfolio and has surpassed the consensus estimate on the topline in each of the trailing four quarters. With the company gearing up to post its third quarter results, is GILD a wise investment now? Read on.

StockNews.com

Bionano Genomics (BNGO) vs. Gilead Sciences (GILD): Buy, Hold or Sell these Biotech Stocks?

As the biotech industry reaches new heights with innovation and the accessibility of big data, let us analyze whether biotech stocks Bionano Genomics and Gilead Sciences are a Buy, Hold, or Sell.

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

The Unexpected Reason Gilead Just Notched Its Biggest Single-Day Move In A Month

Investors don't fully appreciate Gilead Sciences' leadership in HIV treatment, an analyst said Friday as he upgraded GILD stock.

StockNews.com

3 Biotech Stocks With Some Major Value in Them

The worldwide need for healthcare and biotech products is experiencing a steady upsurge fueled by various factors, such as a heightened emphasis on personalized medicine. Therefore, it could be wise to explore three quality biotech stocks, Gilead Sciences (GILD), Biogen (BIIB), and Alkermes (ALKS), with significant value in them. Read…

StockNews.com

3 Biotech Stocks Every Investor Wants

Given inelastic demand, rapid breakthroughs, and government initiatives, the biotech industry looks well-positioned to thrive. So, quality biotech stocks Gilead Sciences (GILD), Biogen (BIIB), and Alkermes (ALKS) could be worth owning. Read on.

Investors Business Daily

Gilead Sciences Stock Reaches 80-Plus Relative Strength Rating Benchmark

Gilead Sciences shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Markets Today: Stocks Slip Ahead of U.S. Debt Ceiling Talks

Morning Markets June E-Mini S&P 500 futures (ESM2 3) this morning are down -0.26%, and June Nasdaq 100 E-Mini futures (NQM2 3) are down -0.21%. U.S. stock index futures this morning are moderately lower as the markets await any new developments on the debt ceiling stalemate. President Biden will meet...

The Independent UK

Pharmaceutical executives challenge Texas court’s abortion pill ruling

Gilead Sciences and Pfizer join amicus brief

StockNews.com

2 Biotech Stocks to Buy Hand Over Fist in March

The biotech industry is expected to expand rapidly, driven by significant advancements and government initiatives. Furthermore, this sector tends to be relatively defensive and holds up relatively well during downturns. So, fundamentally sound biotech stocks Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX) might be ideal buys now. Keep reading.

StockNews.com

3 Dividend Paying Stocks to Buy in March

With the stock market anticipated to stay volatile due to persistent concerns about high inflation, interest rate hikes, and a recession, fundamentally solid dividend stocks Gilead Sciences (GILD), CVS Health (CVS), and Altria (MO) might be great buys for a steady income stream. Keep reading.

StockNews.com

It’s Time to Buy Up These 3 Growth Stocks In 2023

While higher rates have hurt growth stocks last year, 2023 could be the year of growth stocks gaining momentum. Amid rising optimism, investors could consider buying fundamentally strong growth stocks Gilead Sciences (GILD), Jazz (JAZZ), and Masonite International (DOOR) this year. Keep reading.

Investors Business Daily

Gilead Snags Another Cancer Win On The Heels Of Its Best Growth In 7 Years

Gilead Sciences followed up a strong quarterly report with a third FDA approval for cancer drug Trodelvy, and GILD stock popped.

StockNews.com

2 Biotech Stocks to Buy and 1 to Avoid Like the Plague

The biotech industry is expected to witness solid growth driven by growing government initiatives and increasing demand across several sectors. While we think fundamentally sound biotech stocks Gilead Sciences (GILD) and United Therapeutics (UTHR) could be solid buys this year, Bionano Genomics (BNGO) could be best avoided considering its fundamental…

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

SP Global Market Intelligence

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.